1. The problem of oncostatic specificity of cyclophosphamide (NSC-26271): Studies on reactions that control the alkylating and cytotoxic activity;Hohorst;Cancer Treat. Rep.,1976
2. The problem of specificity and selectivity of alkylating cytostatics: Studies on N-2-chloroethylamino-oxazaphosphorines;Brock;Z. Krebsforsch.,1977
3. Evidence for enzymatic toxification of “activated” cyclophosphamide (4-hydroxycyclophosphamide);Voelcker;J. Cancer Res. Clin. Oncol.,1981
4. Enzymatic toxicogenation of “activated” cyclophosphamide by 3′–5′ exonucleases;Bielicki;J. Cancer Res. Clin. Oncol.,1983
5. Studies on 4-hydroperoxycyclophosphamide (NSC-181815): A simple preparation method and its application to the synthesis of a new class of “activated” sulfur-containing cyclophosphamide (NSC-26271) derivatives;Peter;Cancer Treat. Rep.,1976